Glenmark holds firm near record zone, shares trade in a tight NSE range

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 20:53.

Glenmark Pharmaceuticals (INE935A01035) on the NSE trades close to the upper end of its recent range. As of the latest session, the Indian mid-cap pharma name shows a narrow intraday band around ?2,200 per share according to Upstox and exchange data.Upstox live quote and trading range

What the latest prices show

On the National Stock Exchange in Mumbai, Glenmark Pharmaceuticals shares most recently changed hands around ?2,191.70, compared with a previous close of ?2,191.90 as per Upstox.Upstox live quote and trading range During the session, the shares moved between roughly ?2,184 and ?2,235, indicating relatively contained intraday volatility for a stock that has gained strongly over the past twelve months.INDmoney end-of-day price data

Over a six-month horizon, Glenmark shares are up about 7.5 percent, while the year-on-year performance is close to 34 percent, according to Upstox data on the NSE listing.Upstox performance overview This puts the stock among the stronger movers in the Indian pharmaceutical mid-cap segment alongside names such as Lupin and Cipla, which also benefited from consistent domestic demand and US generics exports.

Analyst targets and earnings profile

Consensus data compiled by Investing.com show Glenmark Pharmaceuticals with an average 12?month price target of about ?2,496.50 per share, implying mid?teens percentage upside from current NSE levels.Investing.com analyst summary and targets The same overview cites an EPS on a trailing?twelve?month basis above ?48, reflecting improved profitability after recent portfolio rationalisation.

For the latest reported period, Investing.com lists quarterly sales of roughly ?37,706 crore and net income of about ?3,014 crore for Glenmark Pharmaceuticals, translating into quarterly EPS of around ?10.68.Investing.com financials snapshot On a full?year basis for FY23, Upstox cites revenue of ?12,990 crore, EBITDA of ?2,278.4 crore and profit after tax of ?377.4 crore, underlining a solid, if earnings?volatile, track record in the Indian pharma context.Upstox FY23 financial highlights

The business behind the stock

Glenmark Pharmaceuticals generates most of its revenue from branded generics and specialty formulations in India, Latin America, Central and Eastern Europe, and the United States. The group operates across therapeutic areas including dermatology, respiratory and oncology, supported by in?house active pharmaceutical ingredient (API) development and manufacturing capacity.Upstox company profile and history

Where the shares trade today

The Glenmark Pharmaceuticals shares (INE935A01035) trade on 2026-06-23 at 15:59 India time on the NSE at ?2,179.40 per share.

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities.